New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?
Publication/Presentation Date
10-1-2021
Abstract
Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV.
Volume
39
Issue
10
First Page
619
Last Page
622
ISSN
1873-2496
Published In/Presented At
Hoffman-Censits, J., Lombardo, K., McConkey, D., Hahn, N. M., Bashir, B., Kelly, W. K., Johnson, B., & Matoso, A. (2021). New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?. Urologic oncology, 39(10), 619–622. https://doi.org/10.1016/j.urolonc.2021.05.013
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
34148797
Department(s)
Administration and Leadership
Document Type
Article